Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 5, 2019 | Series E | $7M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Qianhai Ark | — | Series E |